Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Puma Biotechnology, Inc is a biotechnology business based in the US. Puma Biotechnology shares (PBYI) are listed on the NASDAQ and all prices are listed in US Dollars. Puma Biotechnology employs 269 staff and has a trailing 12-month revenue of around USD$235.5 million.
Since the stock market crash in March caused by coronavirus, Puma Biotechnology's share price has had significant negative movement.
Its last market close was USD$9.08, which is 33.24% down on its pre-crash value of USD$13.6 and 65.09% up on the lowest point reached during the March crash when the shares fell as low as USD$5.5.
If you had bought USD$1,000 worth of Puma Biotechnology shares at the start of February 2020, those shares would have been worth USD$917.92 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,129.37.
|Latest market close||USD$9.08|
|52-week range||USD$5.5 - USD$14.95|
|50-day moving average||USD$9.4379|
|200-day moving average||USD$10.1869|
|Wall St. target price||USD$10.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.41|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||N/A|
|1 month (2020-10-30)||8.48%|
|3 months (2020-08-28)||N/A|
|6 months (2020-05-28)||N/A|
|1 year (2019-11-27)||N/A|
|2 years (2018-11-27)||N/A|
|3 years (2017-11-27)||N/A|
|5 years (2015-11-27)||N/A|
Valuing Puma Biotechnology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Puma Biotechnology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Puma Biotechnology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.03. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Puma Biotechnology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$235.5 million|
|Gross profit TTM||USD$235.4 million|
|Return on assets TTM||-6.78%|
|Return on equity TTM||-671.97%|
|Market capitalisation||USD$452.1 million|
TTM: trailing 12 months
There are currently 8.1 million Puma Biotechnology shares held short by investors – that's known as Puma Biotechnology's "short interest". This figure is 1% up from 8.0 million last month.
There are a few different ways that this level of interest in shorting Puma Biotechnology shares can be evaluated.
Puma Biotechnology's "short interest ratio" (SIR) is the quantity of Puma Biotechnology shares currently shorted divided by the average quantity of Puma Biotechnology shares traded daily (recently around 550681.39059305). Puma Biotechnology's SIR currently stands at 14.67. In other words for every 100,000 Puma Biotechnology shares traded daily on the market, roughly 14670 shares are currently held short.
However Puma Biotechnology's short interest can also be evaluated against the total number of Puma Biotechnology shares, or, against the total number of tradable Puma Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Puma Biotechnology's short interest could be expressed as 0.2% of the outstanding shares (for every 100,000 Puma Biotechnology shares in existence, roughly 200 shares are currently held short) or 0.2644% of the tradable shares (for every 100,000 tradable Puma Biotechnology shares, roughly 264 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Puma Biotechnology.
Find out more about how you can short Puma Biotechnology stock.
We're not expecting Puma Biotechnology to pay a dividend over the next 12 months.
Over the last 12 months, Puma Biotechnology's shares have ranged in value from as little as $5.5 up to $14.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Puma Biotechnology's is 1.1917. This would suggest that Puma Biotechnology's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. The company was founded in 2010 and is headquartered in Los Angeles, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.